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Abstract
Background: We aimed to investigate mortality trends in hospitalized patients with septic shock in the US. To
achieve this objective, we tested hypothesis that mortality decreased in patients identified by the code of septic
shock while mortality did not change in those with septic shock identified by vasopressor use.
Methods: We conducted a serial cross-sectional analysis using Nationwide Inpatient Sample database from 2005
through 2011. First, we identified all adult patients aged ≥18 years hospitalized for septic shock by the following
criteria: 1) primary ICD-9 diagnosis of infection plus procedure code for vasopressor use, 2) primary ICD-9 diagnosis
of infection plus septic shock in non-primary field, and 3) primary ICD-9 diagnosis of septic shock. Second, we
stratified all identified patients by record of vasopressor use. The outcome of interest was year-to-year changes in
the in-hospital all-cause mortality.
Results: From 2005 to 2011, we identified 109,812 weighted hospitalizations with septic shock. Overall, there was a
significant downward trend in in-hospital mortality (from 46 % in 2005 to 42 % in 2011; Ptrend = 0.003); the adjusted
mortality also decreased significantly (OR for comparison of 2005 with 2011, 0.98; 95 % CI, 0.96–1.00; P < 0.001).
In stratified analysis, the mortality trend was not significant in the subgroup with vasopressor use (from 42 % in
2005 to 40 % in 2011; Ptrend =0.57); similarly, the adjusted mortality did not change significantly (OR, 1.01; 95 %
CI, 0.97–1.05; P =0.62). By contrast, there was a downward trend in mortality in the subgroup without vasopressor
use (from 47 % in 2005 to 43 % in 2011; Ptrend =0.002); likewise, the adjusted mortality decreased significantly (OR,
0.97; 95 % CI, 0.95–0.99; P =0.002)
Conclusions: From 2005 to 2011, we found a modest decrease in in-hospital mortality among patients identified
with septic shock. However, in the subgroup with vasopressor use, we found no significant change in mortality.
Our data challenge the conventional wisdom that mortality in this population has improved during the last decade.
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Background
Sepsis is a major public health problem in the US, with
the annual national incidence of severe sepsis and septic
shock reaching 3 million in 2009 [1]. Due to the rapid
and steady increase in the number of these patients with
associated healthcare resource use, the total direct costs
for hospitalizations have increased markedly, up from
$15.4 billion in 2003 to $24.3 billion in 2007 [2].
Despite decades of intense research and major techno-
logical advances, mortality for septic shock remains high,
ranging from 22 to 50 % [3–5]. In the US, claim-based
datasets have primarily been used to estimate nationwide
mortality trends for septic patients and shown a decrease
in the estimated mortality [1, 2, 6]. For example, a study
reported that the mortality declined from approximately
40 % in 1998 to 30 % in 2009 [7]. However, the de-
creased mortality may have been overestimated in these
studies [1, 2, 6, 7], owing to an artifact of changes in
diagnostic coding [8–10]. New ICD-9 codes for sepsis
syndromes (sepsis, severe sepsis, septic shock) were intro-
duced in 2002 and 2003. Additionally, increased clinical
vigilance and subsequent coding as a result of awareness
campaigns might result in identification of patients with
less severe illness [8, 11]. Given that variation in the mor-
tality of septic shock depends on the methods used for
database abstraction [1, 2], the actual mortality trend
among patients with septic shock remains largely unclear.
In this context, we investigated mortality trends in US
patients with septic shock by using data from the 2005
to 2011 Nationwide Inpatient Sample. We used a meth-
odological approach that is less sensitive to ambiguous
coding practices and one that identifies a septic popula-
tion with undeniable hemodynamic consequences, (i.e.,
those with documented vasopressor requirement) [9].
We hypothesized that the mortality trend in septic shock
defined by vasopressor use would be unchanged, while
the mortality trend in patients identified based on septic
shock ICD-9 diagnosis code alone would decrease.
Methods
Design and settings
This is a serial cross-sectional analysis using the data
from the 2005 to 2011 releases of the Nationwide In-
patient Sample (NIS). The NIS is the largest all-payer
US inpatient care database, with approximately 8 million
hospitalizations added each year [12]. Developed as part
of the Healthcare Cost and Utilization Project by the
Agency for Healthcare Research and Quality (AHRQ),
the NIS contains a 20 % stratified sample of all short-
term, non-federal, non-rehabilitation hospitals. Stratifi-
cation and weighting variables enable the calculation of
national estimates and temporal trends, accounting for
the complex sampling design and expanded sampling
framework over time. Information on the location of
disposition (e.g., a hospital ward or an intensive care
unit) is not included in the NIS. Up to 25 discharge
diagnoses (increased from 15 codes in 2009) are coded
with the use of the International Classification of Dis-
eases, 9th Revision, Clinical Modification (ICD-9-CM),
with the first-listed diagnosis regarded as the primary
reason for hospitalization. This study was approved by
the institutional review boards of Massachusetts General
Hospital with an informed consent waiver.
Patients
First, on the basis of the general approach of Kumar et
al. [6], we identified all adult patients aged ≥18 years
hospitalized for septic shock by using the following cri-
teria: 1) principal ICD-9-CM diagnosis of infection asso-
ciated with major causes of sepsis (described below) plus
recorded vasopressor use (code, 00.17) in any procedural
field, 2) principal ICD-9-CM diagnosis of infection asso-
ciated with major causes of sepsis plus diagnosis of sep-
tic shock (code, 785.52) in non-primary diagnosis field
(not principal diagnosis) regardless of vasopressor use,
or 3) principal diagnosis of septic shock (code, 785.52)
regardless of vasopressor use. To avoid the misclassifica-
tion and complexity in mortality, we focused on definite,
simple, “septic shock” patients.
Second, we stratified all identified patients by the use
of vasopressor: 1) patients with a recorded use of vaso-
pressor (the subgroup with vasopressor use), and 2)
those without (the subgroup without vasopressor use).
Defining septic shock as ICD-9-CM code for infection
listed as a principal diagnosis paired with the use of a
vasopressor has been established [3, 6, 11, 13]. Because
the proportion of patients with the primary diagnosis of
septic shock accounted for less than 1 % of septic shock
in the current study, we did not stratified by the defini-
tions. To minimize the effect of ambiguous definitions
(e.g., larger list of ICD-9 codes that might denote sus-
pected infection), we focused on the four major causes
of sepsis (see Additional file 1: Table S1) [9, 14–19]:
pneumonia (codes, 481, 482, 483, 485, 486), urinary tract
infection (codes, 590, 595.0, 595.2–4, 595.89, 595.9, 597,
598.00–01, 599.0), abdominal infections (codes, 008.45,
009, 540–542, 543.9, 562.01, 562.03, 562.11, 562.13, 567,
569.5, 569.61, 569.71, 569.83, 572, 574–576, 614, 616),
and bacteremia (code, 790.7) [1, 6, 7, 9, 20].
Covariates
The NIS contains information on patient characteristics,
including demographics (age, sex, and race/ethnicity),
primary insurance type, quartiles for estimated median
household income, and patient comorbidities. Primary
insurance types were categorized into Medicare, Medic-
aid, private, self-pay, and others. To adjust for potential
confounding by patient-mix, 29 Elixhauser comorbidity
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measures were derived based on the ICD-9-CM codes
using the AHRQ Comorbidity Software [21]. This risk
adjustment tool has been validated extensively [22]. As
the NIS does not contain unique patient identifiers, the
unit of analysis was hospital discharge-level.
Hospital characteristics included geographic region,
urban-rural status, teaching status, and hospital control
and ownership. Geographic regions (North, East, South,
Midwest, and West) were defined according to Census
Bureau boundaries. Urban-rural status for the patient
residence was defined based on National Center for
Health Statistics [23].
Outcome measure
The outcome of interest was year-to-year changes in the
in-hospital all-cause mortality. In-hospital mortality was
defined as the number of deaths divided by the total
number of hospitalizations for septic shock.
Statistical analyses
The frequency of hospitalizations for septic shock was
estimated by weighting the patient-level discharge data
in the NIS files using the weights provided. To examine
the mortality trends in the patients with septic shock,
we fit two analytical models. First, we fit an unadjusted
model that included only the calendar year as the inde-
pendent variable. Second, we fit a multivariable logistic
regression model adjusting for both patient-level vari-
ables (age, sex, race/ethnicity, primary payer, household
income, and 29 Elixhauser comorbidity measures) and
hospital-level characteristics (region, hospital control
and ownership, urban and rural distinction, and hospital
teaching status). To address the possibility that adoption
of coding practices over the study period led to an
artifact of declining mortality, we repeated the above
analysis stratified by record of vasopressor use. All
analyses were performed with SAS-callable SUDAAN
statistical software, version 11.0.0 (Research Triangle
Institute, Research Triangle Park, NC, USA). Two-sided
P <0.05 was considered statistically significant.
Results
From 2005 to 2011, overall, we identified 22,260 hospi-
talizations for septic shock in the US, corresponding to
109,812 weighted hospitalizations. Of these, the sub-
group with vasopressor use comprised a weighted esti-
mate of 19,108 (17 %) patients and the subgroup
without vasopressor use comprised a weighted estimate
of 90,705 (83 %) patients. Table 1 shows overall patient
and hospital characteristics over the study period. Over-
all, patients identified as septic shock were more likely
to be aged 60 to 69 years (Ptrend < 0.001) and to have co-
morbidities, such as diabetes, liver disease, renal failure,
and solid tumors (all Ptrend < 0.01). These trends were
also observed both in the subgroup with vasopressor use
(Additional file 1: Table S2) and the subgroup without
vasopressor use (Additional file 1: Table S3).
Mortality trends in patients with septic shock, 2005-2011
Among all patients identified with septic shock, in-
hospital mortality decreased from 46 % in 2005 to 42 %
in 2011 (Ptrend = 0.003; Additional file 1: Table S4). The
multivariable-adjusted mortality also decreased signifi-
cantly from 2005 to 2011 (odds ratio [OR] for comparison
of 2005 with 2011, 0.98; 95 % CI, 0.96–1.00; P < 0.001;
Fig. 1 and Additional file 1: Table S5).
In the stratified analysis, the mortality trend was not
significant in the subgroup with vasopressor use (from
42 % in 2005 to 40 % in 2011; Ptrend =0.57; Additional
file 1: Table S4); similarly, the adjusted mortality did not
change significantly (OR for comparison of 2005 with
2011, 1.01; 95 % CI, 0.97–1.05; P =0.62; Fig. 1 and
Additional file 1: Table S5). By contrast, there was a
downward trend in mortality in the subgroup without
vasopressor use (from 47 % in 2005 to 43 % in 2011;
Ptrend =0.002); likewise, the adjusted mortality decreased
significantly (OR for comparison of 2005 with 2011, 0.97;
95 % CI, 0.95–0.99; P =0.002).
Discussion
In this serial cross-sectional study, using nationally-
representative US samples from 2005 to 2011, we found
an approximate 10 % relative decrease in in-hospital
mortality among all adult patients identified with septic
shock. However, in the subgroup with recorded vaso-
pressor use, we found no significant change in mortality.
In both septic shock subgroups, in-hospital mortality
was unacceptably high, with case fatality rates of greater
than 40 %.
Mortality trends in septic shock have important impli-
cations for clinical practice, research, and policy devel-
opment. In the US, several studies using administrative
data have indicated that the mortality among patients
with septic shock decreased by approximately 6 to 10 %
over the past decade. These reported declines in mortality
might be driven by improvements in treatment strategies
for patients with severe sepsis and septic shock [1, 2, 6].
Alternatively, mortality trends are subject to changes in
the study population [1, 2]. Indeed, a previous study
reporting a decrease in the mortality of septic shock from
1998 to 2009 found a concurrent 6-fold increase in the in-
cidence of hospitalizations for septic shock during the
same period, with an large step-increase around 2003
—the year that the ICD-9-CM specific code for septic
shock (785.52) was created [7]. Similarly, another study
reported a steady increase in hospitalization rates for
sepsis that was paralleled by a stable or decreasing
hospitalization rate for the infections that are the major
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Table 1 Patient and hospital characteristics in the overall patients hospitalized for septic shock in U.S., 2005–2011
Variablesa 2005 2006 2007 2008 2009 2010 2011 Ptrend
Patient characteristics
Unweighted sample, n
Overallb 2827 2783 2996 3381 3438 3442 3393
Subgroup with vasopressor use 484 523 545 518 559 645 607
Subgroup without vasopressor use 2343 2260 2451 2863 2879 2797 2786
Weighted sample, n
Overall 13946 13628 14861 16563 17239 17292 16283
Subgroup with vasopressor use 2392 2566 2664 2494 2789 3293 2910
Subgroup without vasopressor use 11554 11062 12198 14069 14450 13999 13373
Age, y
18–29 2 (1–2) 1 (1–2) 2 (2–3) 2 (2–3) 2 (1–2) 2 (1–3) 2 (1–2) 0.46
30–39 3 (2–4) 3 (3–4) 3 (2–4) 3 (2–3) 3 (2–4) 3 (2–4) 3 (2–3) 0.26
40–49 7 (6–9) 8 (7–9) 9 (8–10) 8 (7–9) 7 (6–8) 8 (7–9) 7 (6–8) 0.26
50–59 15 (13–17) 16 (14–18) 14 (13–16) 16 (14–17) 17 (15–18) 15 (13–16) 16 (14–18) 0.58
60–69 19 (17–21) 19 (17–21) 20 (18–22) 21 (19–23) 21 (20–23) 22 (20–24) 24 (22–26) <0.001
70–79 25 (23–28) 24 (22–27) 25 (22–27) 24 (22–26) 24 (22–26) 24 (22–27) 23 (20–25) 0.02
80–89 23 (20–26) 22 (20–25) 21 (19–24) 22 (19–24) 22 (20–24) 21 (19–23) 21 (19–23) 0.03
≥ 90 5 (4–6) 5 (4–6) 5 (4–6) 5 (4–6) 5 (4–6) 5 (4–6) 5 (4–5) 0.70
Male sex 49 (49–49) 49 (49–49) 50 (50–50) 50 (50–50) 50 (50–50) 50 (50–50) 50 (50–50) 0.09
Race/ethnicity
Non-Hispanic white 61 (54–69) 54 (48–60) 54 (48–60) 57 (52–63) 63 (57–69) 64 (58–70) 65 (59–71) <0.001
Non-Hispanic black 7 (6–9) 10 (8–12) 9 (6–12) 9 (7–11) 8 (7–10) 12 (9–12) 11 (9–13) 0.001
Hispanic 7 (5–9) 10 (8–13) 9 (6–11) 8 (6–10) 9 (7–11) 10 (8–12) 10 (8–13) 0.09
Asian/native/other 4 (3–5) 5 (4–6) 6 (5–7) 6 (5–7) 6 (5–8) 6 (4–7) 6 (5–7) 0.10
Unknown 20 (16–24) 21 (17–26) 22 (18–26) 20 (15–24) 14 (9–18) 9 (6–11) 8 (5–11) <0.001
Primary health insurance
Medicare 66 (60–72) 65 (60–71) 65 (59–70) 64 (59–69) 65 (60–69) 64 (59–69) 64 (60–69) 0.34
Medicaid 10 (08–12) 10 (08–12) 09 (07–11) 11 (09–12) 10 (08–11) 11 (09–13) 11 (09–12) 0.39
Private 19 (17–21) 18 (16–20) 20 (18–23) 20 (17–22) 20 (17–22) 18 (16–21) 19 (17–21) 1.00
Self-pay 4 (3–5) 4 (3–5) 3 (3–4) 3 (3–4) 4 (3–5) 4 (3–5) 3 (2–4) 0.63
Other 2 (1–2) 3 (2–4) 2 (2–3) 2 (1–3) 2 (2–3) 3 (2–3) 3 (2–4) 0.14
Estimated median household income
0–25 percentile 27 (23–30) 28 (23–32) 29 (25–34) 28 (25–32) 28 (25–32) 30 (26–34) 29 (25–32) 0.23
26–50 percentile 26 (23–30) 25 (22–28) 25 (22–28) 26 (23–28) 25 (22–28) 25 (22–27) 24 (21–27) 0.27
51–75 percentile 24 (21–27) 24 (21–27) 23 (21–26) 22 (19–25) 23 (21–26) 24 (21–26) 27 (24–30) 0.11
76–100 percentile 23 (19–28) 23 (19–27) 22 (19–25) 24 (20–28) 23 (20–27) 22 (19–25) 20 (17–23) 0.23
Selected comorbidities
Congestive heart failure 30 (28–33) 31 (29–33) 31 (29–33) 26 (24–28) 28 (26–30) 28 (26–29) 31 (29–33) 0.11
Pulmonary circulation disorders 3 (2–3) 3 (2–3) 5 (4–6) 6 (5–7) 7 (6–8) 7 (6–8) 8 (7–9) <0.001
Diabetes, uncomplicated 15 (13–17) 16 (15–18) 18 (16–19) 19 (17–20) 19 (18–21) 18 (16–19) 21 (19–22) <0.001
Liver disease 5 (4–6) 5 (4–6) 5 (4–6) 5 (4–6) 6 (5–7) 6 (5–7) 7 (6–8) 0.002
Renal failure 14 (13–16) 20 (19–22) 21 (20–23) 21 (19–23) 23 (21–24) 22 (20–23) 24 (22–26) <0.001
Solid tumor without metastasis 4 (4–5) 3 (3–4) 4 (4–5) 4 (3–5) 5 (4–5) 5 (4–5) 5 (5–6) 0.006
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causes of sepsis (e.g., pneumonia) [9]. Furthermore, our
previous study in the emergency department setting found
that the incidence of severe sepsis defined using trad-
itional methods significantly increased from 1994 and
2009, while that for more explicitly-defined sepsis
remained stable [24]. These data collectively suggest that
the higher incidence rates of septic shock might be attrib-
utable to artifact of a change in coding practice, a growing
awareness of septic shock, and possible financial incen-
tives. Indeed, a recent literature has emphasized that the
differences in mortality of septic shock caused by coding
practice [25, 26]. These factors would lead to an increased
use of diagnosis codes that classify hospitalizations as be-
ing related to sepsis [8, 9, 27]. Consequently, patients with
a lower illness severity who previously were not identified
as having the condition would be included in more recent
years [2, 6, 7]. This influx of less severe cases would
thereby lead to an apparent decrease in mortality trend.
To address these concerns, surveillance definitions
that are simple, objective, clinically meaningful, and re-
sistant to ascertainment bias are important [9]. We be-
lieve our restrictive definition (i.e., major sepsis-causing
infections with the use of vasopressor therapy) meets
these criteria and is thus a more specific method for the
identification of patients with septic shock for the fol-
lowing reasons. First, focusing on the four major causes
for sepsis eliminates the use of obscure infection-related
diagnosis codes that fall under “suspected infection”
[11]. Second, clinical consensus is that infected patients
who require vasopressors have clinically-significant sep-
tic shock, and this case definition has been used in pre-
vious studies [3, 13]. Finally, a study period starting in
2005 provides consistency of our definitions over the
study period given that codes for septic shock and vaso-
pressor use were first introduced in 2003. Therefore, our
findings are more likely to reflect the mortality trends of
a like sepsis population over the entire study period
compared to prior studies [1, 2, 6, 7].
The reasons for the observed lack of mortality im-
provement in the subgroup with vasopressor use are
likely multifactorial. First, in contrast to the previous
studies using ICD-9-CM codes linking infection to new
organ dysfunction as way to identify severe sepsis and
septic shock [2, 6, 7, 10], we focused on the sicker popu-
lation. Patients with septic shock requiring vasopressors
are critically ill, and the mortality exceeds 40 % in recent
years [3, 11]. Second, although substantial investment of
resources and advancement in knowledge have undoubt-
edly improved the day-to-day care of critically ill pa-
tients, management continues without a decisive therapy
for septic shock; multiple large trials have failed to im-
prove the case fatality of septic shock [13, 28–33]. It is
also plausible that a gap in intensive care resources (e.g.,
number of intensive care physicians, number of intensive
care beds) [34–38] across the nation might have contrib-
uted to the observed lack of improvement in the mortality.
As septic shock is a common condition that requires a
large proportion of healthcare resources, these docu-
mented disparities in intensive care resources may pose a
roadblock to decreasing nationwide mortality. Moreover,
although the implementation of guidelines and bundles is
known to decrease mortality in the intensive care units
[39, 40], the benefit of guidelines are hampered by the
poor adoption in both resource-rich and resource-poor
Table 1 Patient and hospital characteristics in the overall patients hospitalized for septic shock in U.S., 2005–2011 (Continued)
Hospital characteristics
Region
Northeast 29 (23–35) 26 (22–31) 24 (20–27) 22 (18–25) 20 (17–24) 22 (18–26) 20 (16–24) 0.03
Midwest 21 (18–25) 21 (17–25) 21 (17–25) 25 (21–28) 25 (21–30) 22 (18–27) 23 (19–28) 0.37
South 30 (26–34) 31 (27–34) 31 (27–35) 32 (28–36) 32 (29–35) 37 (32–41) 37 (33–42) 0.02
West 19 (16–22) 22 (19–26) 24 (20–28) 21 (18–25) 23 (19–26) 19 (16–22) 19 (16–22) 0.53
Location/teaching status
Rural 11 (9–13) 8 (7–10) 10 (8–13) 8 (7–9) 9 (7–11) 9 (7–12) 9 (7–12) 0.45
Urban nonteaching 47 (41–53) 42 (37–46) 43 (38–47) 43 (38–47) 45 (40–49) 43 (39–47) 43 (38–47) 0.47
Urban teaching 41 (35–47) 50 (44–56) 47 (41–53) 49 (44–55) 46 (41–52) 48 (41–54) 48 (42–54) 0.57
Hospital control/ownership
Government 27 (23–30) 28 (23–32) 29 (25–34) 28 (25–32) 28 (25–32) 30 (26–34) 29 (25–32) 0.97
Private, non-profit 26 (23–30) 25 (22–28) 25 (22–28) 26 (23–28) 25 (22–28) 25 (22–27) 24 (21–27) 0.18
Private, invest-own 24 (21–27) 24 (21–27) 23 (21–26) 22 (19–25) 23 (21–26) 24 (21–26) 27 (24–30) 0.02
Others 23 (19–28) 23 (19–27) 22 (19–25) 24 (20–28) 23 (20–27) 22 (19–25) 20 (17–23) 0.53
Data are expressed as % (95 % CI) unless otherwise indicated
aPercentages may not equal 100 due to rounding
bThe number of overall patients may not equal the sum of the vasopressor group and non–vasopressor group due to rounding
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environments [41]. Indeed, a study of 165 sites docu-
mented that adherence to the entire management bundle
recommended in the Surviving Sepsis Campaign is only
36 % [42].
Because septic shock is a relatively common public
health problem, and any intensive care unit has account-
ability to provide best practice, our data, in conjunction
with the current literature [9, 29, 30, 38, 39], underscore
the need for continued efforts to improve systems of
care —e.g., an enrichment of intensive care resource and
standardization of management with implementation of
the clinical guidelines. Sepsis presents a great opportun-
ity for such quality improvements.
Our study has several potential limitations. First, the
NIS does not provide granular information on clinical or
physiologic measurements, other drugs administered, or
Do-Not-Attempt-Resuscitation codes, as these clinical
data are not captured in the ICD-9-CM codes. These
factors might have confounded our inferences; however,
we controlled for Elixhauser comorbidity measures as a
surrogate for patient comorbidity in our analysis [43].
Second, the number of patients with septic shock in our
study was smaller compared to other studies [1, 4, 7]. It
is likely that vasopressor use was under-reported in our
study, especially in the first years after adoption of the
new procedure code for vasopressor use. Nevertheless,
our objective was not to examine the incidence but to
investigate the mortality trend in patients with septic
shock who requires the use of vasopressors. And we
found no significant change in mortality in this specific
group of patients. Third, the lack of longitudinal follow-up
data in the HCUP database precludes us from examining
longer-term outcomes. However, the HCUP data are
widely used to investigate the mortality trends [1, 10],
thereby we used in-hospital mortality to maintain the
consistency with the previous literature. Fourth, we did
not examine the differences in mortality between patients
with the primary diagnosis of infection and those with the
primary diagnosis of “septic shock” because of the propor-
tion of patients with the primary diagnosis of septic shock
was less than 1 %. Nevertheless, a recent literature has in-
vestigated the differences by using similar HCUP datasets
[25], and consistent with our observation. Finally, as our
findings focused on the four major infections, caution is
required when extrapolating our results to patients with
septic shock caused by other infections and comparing to
previous observation using the primary diagnosis of sepsis,
severe sepsis, or septic shock [1, 10, 25, 44]. However, the
four selected infections account for more than 80 % of
septic shock; therefore, our data are of likely relevance to
most patients with septic shock [45].
Conclusions
In sum, using a nationally-representative sample, we found
an approximate 10 % relative decrease in in-hospital mor-
tality among all patients identified as septic shock from
2005 to 2011. However, in the subgroup with vasopressor
use (i.e., major sepsis-causing infection plus the use of a
vasopressor), we found no change in in-hospital mortality
during the same period, thus challenging the conventional
wisdom that mortality in this population has improved.
Fig. 1 Trends in Adjusted Mortality for Patients with Septic Shock,
2005–2011. a In patients with septic shock, adjusted mortality
significantly decreased (odds ratio for comparison of 2005 with
2011, 0.98; 95 % CI, 0.96–1.00). b In septic shock patients with
recorded vasopressor use, adjusted mortality did not change
significantly (odds ratio for comparison of 2005 with 2011, 1.01;
95 % CI, 0.97-1.05). c In septic shock patients without recorded
vasopressor use, adjusted mortality significantly decreased (odds
ratio for comparison of 2005 with 2011, 0.97; 95 % CI, 0.95–0.99)
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The case fatality of septic shock remains unacceptably high
over the study period. For researchers, our observations
should motivate further investigation of barriers to the de-
livery of high-quality sepsis care and the development of
novel therapeutic strategies. Because septic shock is an on-
going significant public health burden, policymakers will
need to develop better surveillance systems and promote
continued efforts to improve systems of care.
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